AZN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AstraZeneca is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has strong financial growth and positive developments in its pipeline, the current technical indicators and market sentiment suggest a hold position. The stock's price trend is currently bearish, and there are no immediate signals or catalysts indicating a strong entry point.
The MACD is negative (-3.13) and contracting, indicating bearish momentum. RSI is at 28.933, which is neutral but leaning towards oversold territory. The stock is trading near its S1 support level (183.515), with resistance levels at 187.935 and 192.354. The moving averages are converging, suggesting indecision in price movement.
Hedge funds are significantly increasing their positions in AstraZeneca, with a 166.61% rise in buying activity last quarter.
AstraZeneca's plans to establish innovation centers and manufacturing bases in China for cell therapy and radioconjugate drugs indicate long-term growth potential.
Strong financial performance in Q4 2025, with revenue up 4.11% YoY, net income up 55.07% YoY, and EPS up 55.21% YoY.
The stock price has declined by 2% in the regular market and 0.99% in pre-market trading, indicating bearish sentiment.
The gross margin dropped by 2.70% YoY in Q4 2025, which could indicate cost pressures.
Technical indicators show bearish momentum, with no immediate signs of reversal.
In Q4 2025, AstraZeneca reported a revenue increase of 4.11% YoY to $15.503 billion, net income growth of 55.07% YoY to $2.326 billion, and EPS growth of 55.21% YoY to $1.49. However, the gross margin dropped by 2.70% YoY to 78.89%.
Analysts are generally positive on AstraZeneca, with multiple firms raising price targets and maintaining Buy or Overweight ratings. Guggenheim raised its price target to 16,000 GBp, Morgan Stanley to $219, and Citi initiated coverage with a Buy rating and a 17,000 GBp target. However, Deutsche Bank maintains a Sell rating, citing concerns about the stock's valuation.
